еНаука - преглед

Преглед према Аутор Siritanaratkul, Noppadol

Приказ резултата 1 до 5 од 5
ГодинаНасловАутор(и)Тип резултатаМп-кат.
2017Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trialDavies, Andrew; Merli, Francesco; Mihaljevic, Biljana S ; Mercadal, Santiago; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Genevray, Magali; Zharkov, Artem;
Dixon, Mark; Brewster, Michael; Barrett, Martin; MacDonald, David;
Article
21a+M21a+
2013Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicDavies, AJ; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, M; MacDonald, DKonferencijski rad
Mp kategorija će biti prikazana naknadno.
2012Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with FollicDavies, Andrew J; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, Martin; Macdonald, DavidКонференцијски рад
Мп категорија ће бити приказана накнадно.
2014Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 studyDavies, Andrew; Merli, Francesco; Mihaljević, Biljana ; Siritanaratkul, Noppadol; Solal-Céligny, Phillippe; Barrett, Martin; Berge, Claude; Bittner, Beate; Boehnke, Axel; McIntyre, Christine;
MacDonald, David;
Научни чланак
21a+M21a+ - Водећи међународни часопис категорије M21a+
2013Subcutaneous Rituximab and Chemotherapy Achieves Similar Trough Levels, Safety, and Response as Intravenous Rituximab in First-Line Follicular Lymphoma: Stage 1 Results of the Phase 3 Sabrina StudyDavies, Andrew; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, Martin; Macdonald, DavidКонференцијски рад
Мп категорија ће бити приказана накнадно.